Filing Details
- Accession Number:
- 0001144204-12-026008
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-05-03 20:51:16
- Reporting Period:
- 2012-05-01
- Filing Date:
- 2012-05-03
- Accepted Time:
- 2012-05-03 20:51:16
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
895051 | Entremed Inc | ENMD | Biological Products, (No Disgnostic Substances) (2836) | 581959440 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1542072 | W. Tak Mak | Entremed, Inc. 9640 Medical Center Drive Rockville MD 20850 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2012-05-01 | 352,857 | $0.00 | 365,376 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Warrants (Right to Buy) | Acquisiton | 2012-01-20 | 69,565 | $0.00 | 69,565 | $1.40 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
69,565 | 2012-07-29 | 2017-07-29 | No | 5 | A | Direct |
Footnotes
- Reflects the conversion price of a certain Subordinated Mandatorily Convertible Note ("Convertible Note") acquired in connection with the Company's strategic financing entered into on January 20, 2012 ("Strategic Financing"). The Convertible Note automatically converts into shares of common stock, at the conversion price of $1.15, upon stockholders approval of the Strategic Financing. The conversion price reflects the 10-day average closing sale price of the Company's Common Stock ending on January 20, 2012. The stockholders approved the Strategic Financing at the Company's Annual Stockholders Meeting held on April 30, 2012 ("2012 Annual Meeting").
- Warrants were acquired in connection with the Strategic Financing and become exercisable at any time on or after 90 days following the 2012 Annual Meeting.